File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Book Chapter: Management of Metastatic Nasopharyngeal Carcinoma

TitleManagement of Metastatic Nasopharyngeal Carcinoma
Authors
KeywordsChemotherapy
de novo metastasis
Gemcitabine-cisplatin
Metachronous metastasis
Nasopharyngeal carcinoma
Issue Date2019
PublisherAcademic Press
Citation
Management of Metastatic Nasopharyngeal Carcinoma. In Lee AW, Lung ML, Ng WT (Eds.), Nasopharyngeal Carcinoma: From Etiology to Clinical Practice, p. 313-335. London: Academic Press, 2019 How to Cite?
AbstractExcellent locoregional control can now be achieved in patients with nasopharyngeal cancer (NPC) after chemoradiotherapy delivered by intensity-modulated radiotherapy (IMRT). Distant failure occurs in up to 25%–30% of all patients, and has become the main cause of cancer mortality. As prognosis of patients with metastatic NPC can be variable, assigning patients to different prognostic groups using different prognostic models can facilitate personalized cancer treatment. While gemcitabine-cisplatin doublet emerges as the standard first-line chemotherapy, both nonplatinum and platinum-containing chemotherapy regimens and various targeted therapies can serve as second or later lines of systemic therapy. Apart from standard radiological assessments, Epstein–Barr virus DNA is also an important and unrivalled blood biomarker, which can provide longitudinal monitoring of therapeutic outcome as well as potentially predicting early chemotherapy response. With advent of image-guided high-precision IMRT, there has been a paradigm shift in recent years to offer more ablative local radiotherapy for patients with oligometastasis, and also high dose radiotherapy to the primary tumor in patients with de novo metastasis when appropriate. It is envisaged that intensifying both systemic and local therapy may help confer durable control of the distant, with a view to improving symptom control, quality of life, and even survival.
DescriptionChapter 14
Persistent Identifierhttp://hdl.handle.net/10722/293168
ISBN

 

DC FieldValueLanguage
dc.contributor.authorNgan, KCR-
dc.contributor.authorLi, KWS-
dc.contributor.authorChow, JCH-
dc.contributor.authorYip, TTC-
dc.date.accessioned2020-11-23T08:12:48Z-
dc.date.available2020-11-23T08:12:48Z-
dc.date.issued2019-
dc.identifier.citationManagement of Metastatic Nasopharyngeal Carcinoma. In Lee AW, Lung ML, Ng WT (Eds.), Nasopharyngeal Carcinoma: From Etiology to Clinical Practice, p. 313-335. London: Academic Press, 2019-
dc.identifier.isbn9780128149362-
dc.identifier.urihttp://hdl.handle.net/10722/293168-
dc.descriptionChapter 14-
dc.description.abstractExcellent locoregional control can now be achieved in patients with nasopharyngeal cancer (NPC) after chemoradiotherapy delivered by intensity-modulated radiotherapy (IMRT). Distant failure occurs in up to 25%–30% of all patients, and has become the main cause of cancer mortality. As prognosis of patients with metastatic NPC can be variable, assigning patients to different prognostic groups using different prognostic models can facilitate personalized cancer treatment. While gemcitabine-cisplatin doublet emerges as the standard first-line chemotherapy, both nonplatinum and platinum-containing chemotherapy regimens and various targeted therapies can serve as second or later lines of systemic therapy. Apart from standard radiological assessments, Epstein–Barr virus DNA is also an important and unrivalled blood biomarker, which can provide longitudinal monitoring of therapeutic outcome as well as potentially predicting early chemotherapy response. With advent of image-guided high-precision IMRT, there has been a paradigm shift in recent years to offer more ablative local radiotherapy for patients with oligometastasis, and also high dose radiotherapy to the primary tumor in patients with de novo metastasis when appropriate. It is envisaged that intensifying both systemic and local therapy may help confer durable control of the distant, with a view to improving symptom control, quality of life, and even survival.-
dc.languageeng-
dc.publisherAcademic Press-
dc.relation.ispartofNasopharyngeal Carcinoma: From Etiology to Clinical Practice-
dc.subjectChemotherapy-
dc.subjectde novo metastasis-
dc.subjectGemcitabine-cisplatin-
dc.subjectMetachronous metastasis-
dc.subjectNasopharyngeal carcinoma-
dc.titleManagement of Metastatic Nasopharyngeal Carcinoma-
dc.typeBook_Chapter-
dc.identifier.emailNgan, KCR: rkcngan@hku.hk-
dc.identifier.authorityNgan, KCR=rp02371-
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1016/B978-0-12-814936-2.00014-6-
dc.identifier.hkuros319701-
dc.identifier.spage313-
dc.identifier.epage335-
dc.publisher.placeLondon-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats